Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2024-12-01 Epub Date: 2024-01-11 DOI:10.1080/16078454.2023.2293579

Linquan Zhan, Dai Yuan, Xueling Ge, Mei Ding, Jianhong Wang, Xiangxiang Zhou, Xin Wang

{"title":"Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.","authors":"Linquan Zhan, Dai Yuan, Xueling Ge, Mei Ding, Jianhong Wang, Xiangxiang Zhou, Xin Wang","doi":"10.1080/16078454.2023.2293579","DOIUrl":null,"url":null,"abstract":"Objectives: Multiple myeloma (MM) is a class of malignant plasma cell diseases. An increasing application of autologous stem cell transplantation (ASCT) and anti-myeloma agents represented by proteasome inhibitors (PIs) has improved the response rates and survival of MM patients. Patients progressing within 12 months were recently categorized with functional high-risk (FHR), which could not be clarified by existing genetic risk factors, with poor outcomes. Our study aimed to investigate clinical indices related to FHR and seek prognostic roles in transplant-eligible MM patients.Methods: Demographic and individual baseline clinical characteristics were compared by using the Pearson's chi-square and Mann-Whitney U test. Progression-free survival (PFS) and overall survival (OS) were described by Kaplan-Meier estimates and compared using the log-rank test. Logistic regression analysis was used to assess the association of baseline characteristics at MM diagnosis with FHR status.Results: From 18th January 2010 to 1st December 2022, 216 patients were included and divided into two groups according to the FHR status. There was no difference in baseline data between the two groups. Renal impairment (RI, Scr > 2 mg/dL) was common in MM patients and made sense in FHR status. AST levels were validated as independent predictors for FHR status (p = 0.019).Discussion: Patients with RI or higher AST levels (AST > 40 U/L) tended to have worse outcomes. However, transplants had apparently improved prognoses.Conclusion: Therefore, in the PIs era, transplantations are still effective therapies for transplant-eligible MM patients.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2293579"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2023.2293579","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Multiple myeloma (MM) is a class of malignant plasma cell diseases. An increasing application of autologous stem cell transplantation (ASCT) and anti-myeloma agents represented by proteasome inhibitors (PIs) has improved the response rates and survival of MM patients. Patients progressing within 12 months were recently categorized with functional high-risk (FHR), which could not be clarified by existing genetic risk factors, with poor outcomes. Our study aimed to investigate clinical indices related to FHR and seek prognostic roles in transplant-eligible MM patients.

Methods: Demographic and individual baseline clinical characteristics were compared by using the Pearson's chi-square and Mann-Whitney U test. Progression-free survival (PFS) and overall survival (OS) were described by Kaplan-Meier estimates and compared using the log-rank test. Logistic regression analysis was used to assess the association of baseline characteristics at MM diagnosis with FHR status.

Results: From 18th January 2010 to 1st December 2022, 216 patients were included and divided into two groups according to the FHR status. There was no difference in baseline data between the two groups. Renal impairment (RI, Scr > 2 mg/dL) was common in MM patients and made sense in FHR status. AST levels were validated as independent predictors for FHR status (p = 0.019).

Discussion: Patients with RI or higher AST levels (AST > 40 U/L) tended to have worse outcomes. However, transplants had apparently improved prognoses.

Conclusion: Therefore, in the PIs era, transplantations are still effective therapies for transplant-eligible MM patients.

查看原文本刊更多论文

接受蛋白酶体抑制剂治疗的功能性高危多发性骨髓瘤患者的血清指标：一项回顾性研究。

目标：多发性骨髓瘤（MM）是一类恶性浆细胞疾病：多发性骨髓瘤（MM）是一类恶性浆细胞疾病。自体干细胞移植（ASCT）和以蛋白酶体抑制剂（PIs）为代表的抗骨髓瘤药物的应用日益广泛，提高了多发性骨髓瘤患者的应答率和生存率。最近，病情在12个月内进展的患者被归类为功能性高危（FHR），现有的遗传风险因素无法明确这些患者的预后较差。我们的研究旨在调查与FHR相关的临床指标，并寻找符合移植条件的MM患者的预后作用：方法：采用皮尔逊卡方检验和曼-惠特尼U检验比较人口统计学特征和个体基线临床特征。无进展生存期（PFS）和总生存期（OS）通过卡普兰-梅耶估计值进行描述，并使用对数秩检验进行比较。逻辑回归分析用于评估MM诊断时的基线特征与FHR状态的关联：结果：从2010年1月18日至2022年12月1日，共纳入216例患者，并根据FHR状态分为两组。两组患者的基线数据无差异。肾功能损害（RI，Scr > 2 mg/dL）在 MM 患者中很常见，这与 FHR 状态有关。AST水平被证实是FHR状态的独立预测因子（p = 0.019）：讨论：RI或更高AST水平（AST > 40 U/L）的患者往往预后较差。讨论：RI 或 AST 水平较高（AST > 40 U/L）的患者预后较差，但移植后预后明显改善：因此，在 PIs 时代，对于符合移植条件的 MM 患者，移植仍然是有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.